FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

NME Review Program Meeting Goals: Comments

[ Price : $8.95]

PhRMA and BIO say that a PDUFA 5 program to improve transparency and communication in reviewing NDAs and BLAs with new molecular e...

FDA Accepts CardioFocus PMA for Heart Ablation Device

[ Price : $8.95]

FDA accepts for review a CardioFocus PMA for the HeartLight Endoscopic Ablation System for treating atrial fibrillation.

FDA Changing Clozapine Requirements

[ Price : $8.95]

FDA announces drug safety changes for clozapine labeling involving monitoring for neutropenia and a new shared REMS.

Amicus Plans NDA for Fabry Disease Drug

[ Price : $8.95]

Amicus Therapeutics says it plans to submit an NDA for migalastat for treating Fabry disease.

FDA Panel Backs Flu Vaccine for Elderly

[ Price : $8.95]

FDAs Vaccines and Related Biological Products Advisory Committee recommends accelerated approval for a NVS Influenza Vaccines BLA ...

FDA Approves Octapharma NDA for Nuwiq

[ Price : $8.95]

FDA approves an Octapharma NDA for Nuwiq (antihemophilic factor-recombinant), indicated for treating adults and children living wi...

Obama Nominates Califf as Next FDA Commissioner

[ Price : $8.95]

President Obama nominates FDA deputy commissioner for medical products and tobacco Robert M. Califf as the agencys next commission...

GPhA Controlled Correspondence Concerns

[ Price : $8.95]

The Generic Pharmaceutical Association says that an FDA draft guidance on controlled correspondence is counter to provisions in th...

MAPP on CDER Medical Policy Council

[ Price : $8.95]

CDER issues a MAPP on the organization and work of the Centers Medical Policy Council.

Latest FDA Warning Letters

[ Price : $8.95]

In its latest batch of Warning Letters, FDA cites Coram Healthcare Corp. of Indiana dba Coram CVS/Specialty Infusion Services, Jay...